An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; Deregulation of targetable tyrosine kinase receptors

Laboratory Investigation

Volumn 91, Issue 3, 2011, Pages 392-403

  Peng, Tingsheng ^a   Zhang, Pingyu ^a   Liu, Jeffery ^a   Nguyen, Theresa ^a   Bolshakov, Svetlana ^a   Belousov, Roman ^a   Young, Eric D ^a   Wang, Xiaoke ^b   Brewer, Kari ^a   López Terrada, Delores H ^c   Oliveira, Andre M ^b   Lazar, Alexander J ^a,d   Lev, Dina ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

adipogenesis; dedifferentiated liposarcoma; preclinical experimental model; targeted therapy; tyrosine kinase receptors; well differentiated liposarcoma

Indexed keywords

BETA ACTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLIN DEPENDENT KINASE 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN TYROSINE PHOSPHATASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR;

ADIPOCYTE; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSARCOMA; MALE; MDM2 GENE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OIL RED O STAINING; PHENOTYPE; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SCID MOUSE; STAINING; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL MARKERS; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; FEMALE; HUMANS; LIPOSARCOMA; MALE; MICE; MICE, SCID; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951956838     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.185     Document Type: Article

References (39)

1. Dei Tos AP, Pedeutour F. Atypical lipomatous tumor/well differentiated liposarcoma and dedifferentiated liposarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds) Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC: Lyon, 2002, p 35-39.
2. Lahat G, Anaya DA, Wang X, et al. Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol 2008; 15:1585-1593.
3. Evans HL. Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol 1979;3:507-523. (Pubitemid 10203768)
4. Evans HL. Atypical lipomatous tumor, its variants, and its combined forms: a study of 61 cases, with a minimum follow-up of 10 years. Am J Surg Pathol 2007;31:1-14. (Pubitemid 46036897)
5. Weiss SW, Goldblum JR. Liposarcoma. In: Weiss SW, Goldblum JR (eds) Enzinger and Weiss's Soft Tissue Tumors. Mosby: St Louis, 2008, p 477-516.
6. Henricks WH, Chu YC, Goldblum JR, et al. Dedifferentiated liposarcoma. A clinicopathologic analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997; 21:271-281. (Pubitemid 27120195)
7. McCormick D, Mentzel T, Beham A, et al. Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol 1994; 18:1213-1223. (Pubitemid 24362434)
8. Kimberly MD, Cristina RA, Samuel S. Diagnosis and management of lipomatous tumors. J Surg Oncol 2008;97:298-313.
9. Takahira T, Oda Y, Tamiya S, et al. Alterations of the RB1 gene in dedifferentiated liposarcoma. Mod Pathol 2005;18:1461-1470. (Pubitemid 41509401)
10. Micci F, Bjerkehagen B, Heim S. Pairwise comparison of genomic imbalances between primary and recurrent well differentiated liposarcomas. Cancer Genet Cytogenet 2007;178:163-167. (Pubitemid 47595355)
11. Pedeutour F, Forus A, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999;24:30-41. (Pubitemid 28544460)
12. Italiano A, Blanchini L, Keslair F, et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinctive inconsistent amplicon. Int J Cancer 2008; 122:2233-2241. (Pubitemid 351542325)
13. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29. (Pubitemid 30064488)
14. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87. (Pubitemid 34311901)
15. Fritz B, Schubert F, Wrobel G, et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002;62:2993-2998. (Pubitemid 34602383)
16. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626-6636. (Pubitemid 47105508)
17. Matushansky I, Hernando E, Socci ND, et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Path 2008;17:1069-1080. (Pubitemid 351520003)
18. Debrock G, Vanhentenrijk V, Sciot R, et al. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003;89:1409-1412. (Pubitemid 37386592)
19. Snyder EL, Sandstrom DJ, Law K, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 2009;218:292-300.
20. Ramírez-Zacarías JL, Castro-Muñozledo F, Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 1992;97:493-497.
21. Lahat G, Zhu QS, Huang KL, et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010;5:e10105.
22. Weaver J, Downs-Kelly E, Goldblum JR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol 2008;21:943-949.
23. Chibon F, Mariani O, Derré J, et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Gen Cytogenet 2002;139: 24-29. (Pubitemid 36120402)
24. Shimoji T, Kanda H, Kitagawa T, et al. Clinico-molecular study of dedifferentiation in well-differentiated liposarcoma. Biochem Biophys Res Commun 2004;314:1133-1140. (Pubitemid 38142401)
25. Horvai AE, DeVries S, Roy R, et al. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol 2009;22:1477-1488.
26. Mai HE, Aisner S, Benevenia J, et al. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma. Pathol Res Pract 2009;205: 386-394.
27. Coindre JM, Pédeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010;456:167-179.
28. Trahan S, Erickson-Johnson MR, Rodriguez F, et al. Formation of the 12q14-q15 amplicon precedes the development of a welldifferentiated liposarcoma arising from a nonchondroid pulmonary hamartoma. Am J Surg Pathol 2006;30:1326-1329. (Pubitemid 44454714)
29. Aleixo PB, Hartmann AA, Menezes IC, et al. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 2009;62:1127-1135.
30. Hélias-Rodzewicz Z, Pédeutour F, Coindre JM, et al. Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. Genes Chromosomes Cancer 2009;48:943-952.
31. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci 1997;94:237-241. (Pubitemid 27027193)
32. Mü ller CR, Paulsen EB, Noordhuis P, et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007;121:199-205.
33. Pires de Camargo V, van de Rijn M, Maestro R, et al. Other targetable sarcomas. Semin Oncol 2009;36:358-371.
34. Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009;15:5696-5703.
35. Mariani O, Brennetot C, Coindre JM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007;11:361-374. (Pubitemid 46518313)
36. Michaud K, Solomon DA, Oermann E, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-3238.
37. Shrotriya S, Kundu JK, Na HK, et al. Diallyl trisulfide inhibits phorbol ester-induced tumor promotion, activation of AP-1, and expression of COX-2 in mouse skin by blocking JNK and Akt signaling. Cancer Res 2010;70:1932-1940.
38. Harrington M, Pond-Tor S, Boney CM. Role of epidermal growth factor and ErbB2 receptors in 3T3-L1 adipogenesis. Obesity 2007; 15:563-571. (Pubitemid 46643308)
39. Lee JS, Suh JM, Park HG, et al. Heparin-binding epidermal growth factorlike growth factor inhibits adipocyte differentiation at commitment and early induction stages. Differentiation 2008;76:478-487. (Pubitemid 351725838)